Purpura

Your skin is a mirror of your health – here’s what yours might be saying

Retrieved on: 
Tuesday, January 30, 2024

It is the largest and most visible organ in the human body.

Key Points: 
  • It is the largest and most visible organ in the human body.
  • Being the most visible of our organs, the skin also offers us a view into the body tissues that it protects.
  • So don’t think of your skin merely aesthetically – think of it as a reflection of your health.

Bullseye

  • But while the vast majority of tick bites won’t make you ill, there is one rash that should prompt a visit to your doctor if you spot it.
  • Erythema migrans, a rash named for its ability to rapidly expand across the skin, is a hallmark of Lyme disease, a potentially severe bacterial illness.
  • This rash forms a classic target pattern, like a bullseye on a dartboard.

Purpura

  • Some rashes are given a colourful namesake – purpura is one such example.
  • Purpura refers to a rash of small purple or red dots.
  • Purpura signals an issue with either the walls of the tiny blood vessels that feed the skin or the blood within them.

Skin spiders


Skin rashes can also take on recognisable shapes. Spider naevi represent an issue within skin arterioles (small arteries which supply the skin with blood). Arterioles open and close to control the loss of heat from the body’s surface. But sometimes they can get stuck open – and a spider-like pattern will appear.

  • Crush the body under a fingertip and the whole thing disappears, as your touch temporarily stops the blood flow.
  • Treat the underlying cause, and the spiders often vanish with time – though they may persist or reappear later.

Black velvet

  • This “black velvet” skin appearance is more commonly seen in darker skins.
  • Usually, the condition is associated with disorders of the metabolism – namely type 2 diabetes and polycystic ovary syndrome.

Butterfly rashes

  • Cardiac valves have the important role of correctly directing the journey of blood through the heart and preventing backflow.
  • The body’s natural response is to preserve core blood volume, shutting off flow towards the skin.
  • The net effect can produce a purple-red rash, high across the cheeks and the bridge of the nose, like the outstretched wings of a butterfly.


Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Pre-Eclampsia Drug Pipeline Research Report 2023: Comprehensive Insights into 5+ Companies and Portfolios of 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 14, 2023

Discover the dynamic landscape of Pre-Eclampsia research with our report, offering comprehensive insights into 5+ leading companies and their portfolios of 5+ pipeline drugs.

Key Points: 
  • Discover the dynamic landscape of Pre-Eclampsia research with our report, offering comprehensive insights into 5+ leading companies and their portfolios of 5+ pipeline drugs.
  • Our report also shines a light on inactive pipeline projects within this domain.
  • Dive into our thorough assessment, which encompasses a comprehensive commercial evaluation of Pre-Eclampsia alongside a clinical analysis of ongoing pipeline projects.
  • Experience the collaborative efforts of companies and academic institutions as they tackle challenges and explore opportunities within Pre-Eclampsia research and development.

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

Retrieved on: 
Friday, June 9, 2023

“Based on this interim update of five patients treated, we remain confident in the potential of our approach to enable targeted therapies post-transplant.

Key Points: 
  • “Based on this interim update of five patients treated, we remain confident in the potential of our approach to enable targeted therapies post-transplant.
  • Investigator enthusiasm is strong and proposal of patients for enrollment in the study currently exceeds the enrollment stagger.
  • We look forward to sharing further engraftment and hematologic protection data from additional patients treated by year-end,” said Eyal Attar, MD, Vor Bio Chief Medical Officer.
  • Patients 4 and 5 achieved normal neutrophil engraftment and platelet recovery, providing further confidence in the Company’s platform and approach.

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Retrieved on: 
Tuesday, May 30, 2023

Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.
  • “These results support the potential for marstacimab to become the first once-weekly non-factor treatment for people with hemophilia B and a treatment option that helps address the diverse needs of patients with hemophilia A or B without inhibitors.
  • The safety profile for marstacimab was consistent with Phase 1/2 results and treatment was generally well-tolerated.
  • Pfizer currently has three Phase 3 programs investigating novel treatment options for people living with hemophilia.

ExchangeRight Expands Broker-Dealer and RIA Relations Team With Tom Purpura, SVP

Retrieved on: 
Friday, May 19, 2023

Purpura will serve advisors, representatives, and investors in Arkansas, Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, and Wisconsin.

Key Points: 
  • Purpura will serve advisors, representatives, and investors in Arkansas, Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, and Wisconsin.
  • ExchangeRight Expands Broker-Dealer and RIA Relations Team With Tom Purpura, SVP
    "Adding Tom to our already exceptional team will help us to better serve representatives, advisors, and investors in the Great Lakes region," said Warren Thomas, one of the managing partners of ExchangeRight.
  • "We are grateful to have Tom join our efforts to empower people to be secure, free, and generous."
  • "ExchangeRight is well known in the alternatives industry for its perfect track record of meeting or exceeding expectations even through economic downturns," Purpura said.

Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 14, 2023

There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets.

Key Points: 
  • There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets.
  • There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist.
  • Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years.
  • The publisher's Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Advanced Infusion Care (AIC) now offers Kedrion Biopharma infusion therapy GAMMAKED™ [Immune Globulin Injection (Human) 10% Caprylate/Chromatography Purified]

Retrieved on: 
Thursday, March 9, 2023

The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized in-home infusion services.

Key Points: 
  • The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized in-home infusion services.
  • This new therapy option, offered under a limited distribution contract with Kedrion, expands AIC’s ability to serve immunoglobulin (Ig) infusion patients.
  • “We’re proud to be able to add GAMMAKED™ to our growing list of Ig infusion therapies,” said Jud Hall, President at AIC.
  • AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other infusion services providers.

Mela Water to Debut at Natural Products Expo West as One of the Industry's "Hot Products" to Watch

Retrieved on: 
Thursday, March 2, 2023

LOS ANGELES, March 2, 2023 /PRNewswire-PRWeb/ -- Mela Water, a line of bold, crisp and naturally sweet watermelon water, is set to make a splashy debut at Natural Products Expo West in its backyard of Southern California, March 8-10th.

Key Points: 
  • The Mela Water team will be hydrating showgoers in North Hall Level 100: Hot Products, Booth #N1107.
  • Mela Water's Expo West debut comes as Mela signs on with UNFI and Rainforest Distribution to increase its footprint across the U.S., tapping into the powerhouse distributors' 30,000- and 3,000-strong retail networks, respectively.
  • "This is the year Mela takes the industry by storm, from the halls of Expo West to retail shelves across the country," said Dominic Purpura, CEO and founder of Mela Water.
  • To learn more and shop for Mela Water, visit https://melawater.com/ and follow along on Instagram ( @mela ) and TikTok ( @melawater ).

Intravenous Immunoglobulin Global Market Report 2022: Rising Prevalence of Immunodeficiency Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022

Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.

Key Points: 
  • Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.
  • Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD.
  • Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.
  • Based on distribution channel, the intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others.

Christine Whichard Earns Top Cybersecurity Spot at SmartBear with Promotion to CISO

Retrieved on: 
Wednesday, August 10, 2022

SmartBear , a leading provider of software development and visibility tools, has promoted Christine Whichard to Chief Information Security Officer (CISO), supporting the companys global offices.

Key Points: 
  • SmartBear , a leading provider of software development and visibility tools, has promoted Christine Whichard to Chief Information Security Officer (CISO), supporting the companys global offices.
  • Christine joined SmartBear more than four years ago and has been an instrumental leader in the companys cybersecurity plans, including an overhaul of its Information Security program.
  • As our deep commitment to information security advances, I am proud to have Christine as our CISO at SmartBear, continuing to scale and innovate our cybersecurity program.
  • Prior to SmartBear, Christine was SVP, Client Engagement and Operations at Videology (now part of Amobee) for nearly seven years.